Table 1.
Therapeutic drugs interacting with Fe-S clusters.
| Drug | Therapeutical property | Therapeutic indication | Fe-S cluster-containing target | Mechanism | Reference |
|---|---|---|---|---|---|
| Hydroxyurea | Antiproliferative | Sickle cell disease, leukemia, polycythemia vera, other cancers | Leu1 | ROS-mediated | [79] |
| Primaquine | Antiparasite | Malaria | Rli1, aconitase | Fe-S cluster interaction and ROS-mediated | [88] |
| MAD-28 (cluvenone derivative) | Antiproliferative | Cancer | MitoNEET, NAF-1 | Fe-S cluster destabilization | [57] |
| Cluvenone | Proapoptotic | Acute lymphoblastic leukemia | MitoNEET, NAF-1 | Fe-S cluster stabilization | [56, 57] |
| Pioglitazone (thiazolidinedione family) | Antidiabetes insulin sensitizer | Diabetes | MitoNEET, NAF-1 | Fe-S cluster stabilization | [67, 70, 71] |
| ‘882 | Antimicrobial | SUF machinery | Binding to Fe-S cluster biogenesis machinery | [80] | |
| Antibiotics | Antimicrobial | Bacterial infections | ROS-mediated (still a matter of debate) | [35, 41–43, 47] | |
| β-Phenethyl isothiocyanate (PEITC) | Antiproliferative | Leukemia | NADH dehydrogenase 3 (respiratory complex I) | ROS-mediated | [48] |
| BC1 | Antiangiogenic, antitumor | Ehrlich carcinoma | ROS-mediated | [49] |